Ephrin-A5 deficiency alters sensorimotor and monoaminergic development

Behavioural Brain Research

Volumn 236, Issue 1, 2013, Pages 139-147

  Sheleg, Michal ^a   Yochum, Carrie L ^b,d   Wagner, George C ^b,c   Zhou, Renping ^a   Richardson, Jason R ^b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Eph receptor; Hanging wire grip strength; Mid air righting; Motor activity; Negative geotaxis

Indexed keywords

DOPAMINE TRANSPORTER; EPHRIN A5; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; FEMALE; LOCOMOTION; MALE; MONOAMINERGIC SYSTEM; MOTOR ACTIVITY; MOTOR DEVELOPMENT; MOTOR PERFORMANCE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORIMOTOR FUNCTION; WEIGHT CHANGE;

AGING; ANIMALS; AXONS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BLOTTING, WESTERN; BODY WEIGHT; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EPHRIN-A5; EYE; GENOTYPE; HAND STRENGTH; INTERPERSONAL RELATIONS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR NEURONS; NEOSTRIATUM; NERVOUS SYSTEM; PLAY AND PLAYTHINGS; POSTURAL BALANCE; REAL-TIME POLYMERASE CHAIN REACTION; SENSORY RECEPTOR CELLS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84866157129     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.08.032     Document Type: Article

References (44)

1. Palmer A., Klein R. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes & Development 2003, 17:1429-1450.
2. Klein R. Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nature Neuroscience 2009, 12:15-20.
3. Reber M., Hindges R., Lemke G. Eph receptors and ephrin ligands in axon guidance. Advances in Experimental Medicine and Biology 2007, 621:32-49.
4. Wilkinson D.G. Multiple roles of EPH receptors and ephrins in neural development. Nature Reviews Neuroscience 2001, 2:155-164.
5. Daar I.O. Non-SH2/PDZ reverse signaling by ephrins. Seminars in Cell & Developmental Biology 2011.
6. Pasquale E.B. Eph receptor signalling casts a wide net on cell behaviour. Nature Reviews Molecular Cell Biology 2005, 6:462-475.
7. Xu N.J., Henkemeyer M. Ephrin reverse signaling in axon guidance and synaptogenesis. Seminars in Cell & Developmental Biology 2011.
8. Adams R.H., Eichmann A. Axon guidance molecules in vascular patterning. Cold Spring Harbor Perspectives in Biology 2010, 2:a001875.
9. Pasquale E.B. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008, 133:38-52.
10. Feldheim D.A., O'Leary D.D. Visual map development: bidirectional signaling, bifunctional guidance molecules, and competition. Cold Spring Harbor Perspectives in Biology 2010, 2:a001768.
11. Klein R. Eph/ephrin signaling in morphogenesis, neural development and plasticity. Current Opinion in Cell Biology 2004, 16:580-589.
12. Brownlee H., Gao P.P., Frisen J., Dreyfus C., Zhou R., Black I.B. Multiple ephrins regulate hippocampal neurite outgrowth. The Journal of Comparative Neurology 2000, 425:315-322.
13. Chen Z.Y., Sun C., Reuhl K., Bergemann A., Henkemeyer M., Zhou R. Abnormal hippocampal axon bundling in EphB receptor mutant mice. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2004, 24:2366-2374.
14. Bolz J., Uziel D., Muhlfriedel S., Gullmar A., Peuckert C., Zarbalis K., et al. Multiple roles of ephrins during the formation of thalamocortical projections: maps and more. Journal of Neurobiology 2004, 59:82-94.
15. Deschamps C., Morel M., Janet T., Page G., Jaber M., Gaillard A., et al. EphrinA5 protein distribution in the developing mouse brain. BMC Neuroscience 2010, 11:105.
16. Zhang J.H., Cerretti D.P., Yu T., Flanagan J.G., Zhou R. Detection of ligands in regions anatomically connected to neurons expressing the Eph receptor Bsk: potential roles in neuron-target interaction. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 1996, 16:7182-7192.
17. Gao W.Q., Shinsky N., Armanini M.P., Moran P., Zheng J.L., Mendoza-Ramirez J.L., et al. Regulation of hippocampal synaptic plasticity by the tyrosine kinase receptor, REK7/EphA5, and its ligand, AL-1/Ephrin-A5. Molecular and Cellular Neurosciences 1998, 11:247-259.
18. Zarbalis K., Wurst W. Expression domains of murine ephrin-A5 in the pituitary and hypothalamus. Mechanisms of Development 2000, 93:165-168.
19. Cutforth T., Moring L., Mendelsohn M., Nemes A., Shah N.M., Kim M.M., et al. Axonal ephrin-As and odorant receptors: coordinate determination of the olfactory sensory map. Cell 2003, 114:311-322.
20. Cooper M.A., Kobayashi K., Zhou R. Ephrin-A5 regulates the formation of the ascending midbrain dopaminergic pathways. Developmental Neurobiology 2009, 69:36-46.
21. Passante L., Gaspard N., Degraeve M., Frisen J., Kullander K., De Maertelaer V., et al. Temporal regulation of ephrin/Eph signalling is required for the spatial patterning of the mammalian striatum. Development 2008, 135:3281-3290.
22. Robinson D.L., Zitzman D.L., Williams S.K. Mesolimbic dopamine transients in motivated behaviors: focus on maternal behavior. Frontiers in Psychiatry/Frontiers Research Foundation 2011, 2:23.
23. Frisen J., Yates P.A., McLaughlin T., Friedman G.C., O'Leary D.D., Barbacid M. Ephrin-A5 (AL-1/RAGS) is essential for proper retinal axon guidance and topographic mapping in the mammalian visual system. Neuron 1998, 20:235-243.
24. Crawley J.N. What's wrong with my mouse: behavioral phenotyping of transgenic and knockout mice 2000, John Wiley & Sons, New-York.
25. Schuh R.A., Richardson J.R., Gupta R.K., Flaws J.A., Fiskum G. Effects of the organochlorine pesticide methoxychlor on dopamine metabolites and transporters in the mouse brain. Neurotoxicology 2009, 30:274-280.
26. Caudle W.M., Richardson J.R., Wang M., Miller G.W. Perinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum. Neurotoxicology 2005, 26:721-728.
27. Maletic V., Robinson M., Oakes T., Iyengar S., Ball S.G., Russell J. Neurobiology of depression: an integrated view of key findings. International Journal of Clinical Practice 2007, 61:2030-2040.
28. Parkitna J.R., Bilbao A., Rieker C., Engblom D., Piechota M., Nordheim A., et al. Loss of the serum response factor in the dopamine system leads to hyperactivity. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2010, 24:2427-2435.
29. Bush G. Cingulate, frontal, and parietal cortical dysfunction in attention-deficit/hyperactivity disorder. Biological Psychiatry 2011, 69:1160-1167.
30. Emond V., Joyal C., Poissant H. Structural and functional neuroanatomy of attention-deficit hyperactivity disorder (ADHD). L'Encephale 2009, 35:107-114.
31. Poelmans G., Pauls D.L., Buitelaar J.K., Franke B. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. The American Journal of Psychiatry 2011, 168:365-377.
32. Lesch K.P., Timmesfeld N., Renner T.J., Halperin R., Roser C., Nguyen T.T., et al. Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. Journal of Neural Transmission 2008, 115:1573-1585.
33. Sandau U.S., Alderman Z., Corfas G., Ojeda S.R., Raber J. Astrocyte-specific disruption of SynCAM1 signaling results in ADHD-like behavioral manifestations. PLoS ONE 2012, 7:e36424.
34. Gilbert D.L., Isaacs K.M., Augusta M., Macneil L.K., Mostofsky S.H. Motor cortex inhibition: a marker of ADHD behavior and motor development in children. Neurology 2011, 76:615-621.
35. Faraone S.V., Mick E. Molecular genetics of attention deficit hyperactivity disorder. The Psychiatric Clinics of North America 2010, 33:159-180.
36. Meijer W.M., Faber A., van den Ban E., Tobi H. Current issues around the pharmacotherapy of ADHD in children and adults. Pharmacy World & Science: PWS 2009, 31:509-516.
37. Zametkin A.J., Rapoport J.L. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years?. Journal of the American Academy of Child and Adolescent Psychiatry 1987, 26:676-686.
38. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:9938-9943.
39. Zhou Q.Y., Quaife C.J., Palmiter R.D. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 1995, 374:640-643.
40. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2007, 27:8138-8148.
41. Taylor T.N., Caudle W.M., Shepherd K.R., Noorian A., Jackson C.R., Iuvone P.M., et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2009, 29:8103-8113.
42. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
43. Volkow N.D., Wang G.J., Newcorn J., Fowler J.S., Telang F., Solanto M.V., et al. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. NeuroImage 2007, 34:1182-1190.
44. Toren P., Rehavi M., Luski A., Roz N., Laor N., Lask M., et al. Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder. European neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2005, 15:159-162.